456 related articles for article (PubMed ID: 9172813)
61. The effect of short G-CSF administration on the numbers and clonogenic efficiency of hematopoietic progenitor cells in bone marrow and peripheral blood of normal donors.
Zaucha JM; Knopińska-Posłuszny W; Bieniaszewska M; Myśliwski A; Hellmann A
Ann Transplant; 2000; 5(4):20-6. PubMed ID: 11499355
[TBL] [Abstract][Full Text] [Related]
62. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
63. [Kinetics of circulating hematopoietic stem cells following chemotherapy in patients with hematopoietic malignancies].
Tamura K; Kosaka M; Mizuguchi T; Miyamoto Y
Rinsho Ketsueki; 1990 May; 31(5):647-54. PubMed ID: 1697629
[TBL] [Abstract][Full Text] [Related]
64. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.
Venturini M; Del Mastro L; Melioli G; Balleari E; Garrone O; Pasquetti W; Bason C; Ghio R; Bruzzi P; Rosso R
Cancer; 1994 Oct; 74(8):2300-6. PubMed ID: 7522948
[TBL] [Abstract][Full Text] [Related]
65. [Clinical significance of recombinant human granulocyte colony-stimulating factor (rG-CSF) in the chemotherapy of patients with malignant lymphoma].
Kuzuyama Y; Sonoda Y; Okuda T; Takashima T; Misawa S; Kashima K; Nakagawa H; Fujii H; Abe T
Rinsho Ketsueki; 1992 Dec; 33(12):1789-96. PubMed ID: 1282572
[TBL] [Abstract][Full Text] [Related]
66. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma.
Zimmerman TM; Michelson GC; Mick R; Grinblatt DL; Williams SF
J Clin Apher; 1999; 14(1):31-4. PubMed ID: 10355661
[TBL] [Abstract][Full Text] [Related]
67. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas.
Brice P; Divine M; Marolleau JP; Haioun C; Dalcortivo L; Sitthy X; Beaujean F; Norol F; Benbunan M; Reyes F
Bone Marrow Transplant; 1994 Jul; 14(1):51-5. PubMed ID: 7524907
[TBL] [Abstract][Full Text] [Related]
68. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man.
Socinski MA; Cannistra SA; Elias A; Antman KH; Schnipper L; Griffin JD
Lancet; 1988 May; 1(8596):1194-8. PubMed ID: 2897009
[TBL] [Abstract][Full Text] [Related]
69. Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF.
Okabe M; Maekawa I; Suzuki S; Higuchi M; Morioka M; Nishi K; Itaya T; Ohmura T; Kawamura M; Fuzimoto N
Leuk Lymphoma; 1995 Nov; 19(5-6):485-91. PubMed ID: 8590851
[TBL] [Abstract][Full Text] [Related]
70. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
[TBL] [Abstract][Full Text] [Related]
71. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
72. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.
Ricca I; Compagno M; Ladetto M; Rocci A; Dell'Aquila M; Omedè P; De Marco F; D'Antico S; Caracciolo D; Ferrero D; Carlo-Stella C; Tarella C
Leukemia; 2005 Apr; 19(4):644-51. PubMed ID: 15716989
[TBL] [Abstract][Full Text] [Related]
73. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
74. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
Kaplan LD; Kahn JO; Crowe S; Northfelt D; Neville P; Grossberg H; Abrams DI; Tracey J; Mills J; Volberding PA
J Clin Oncol; 1991 Jun; 9(6):929-40. PubMed ID: 2033429
[TBL] [Abstract][Full Text] [Related]
75. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
76. High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.
Hyun SY; Cheong JW; Kim SJ; Min YH; Yang DH; Ahn JS; Lee WS; Ryoo HM; Do YR; Lee HS; Lee JH; Oh SY; Suh C; Yhim HY; Kim JS
Biol Blood Marrow Transplant; 2014 Jan; 20(1):73-9. PubMed ID: 24141009
[TBL] [Abstract][Full Text] [Related]
77. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
Winter JN; Lazarus HM; Rademaker A; Villa M; Mangan C; Tallman M; Jahnke L; Gordon L; Newman S; Byrd K; Cooper BW; Horvath N; Crum E; Stadtmauer EA; Conklin E; Bauman A; Martin J; Goolsby C; Gerson SL; Bender J; O'Gorman M
J Clin Oncol; 1996 Jan; 14(1):277-86. PubMed ID: 8558209
[TBL] [Abstract][Full Text] [Related]
78. Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment.
Robinson SN; Freedman AS; Neuberg DS; Nadler LM; Mauch PM
Exp Hematol; 2000 Dec; 28(12):1325-33. PubMed ID: 11146154
[TBL] [Abstract][Full Text] [Related]
79. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
[TBL] [Abstract][Full Text] [Related]
80. The collection and evaluation of peripheral blood progenitor cells sufficient for repetitive cycles of high-dose chemotherapy support.
Benjamin RJ; Linsley L; Axelrod JD; Churchill WH; Sieff C; Shulman LN; Elias A; Ayash L; Malachowski ME; Uhl L
Transfusion; 1995 Oct; 35(10):837-44. PubMed ID: 7570914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
